title: Interferon (alpha, beta and omega) receptor 2 is a prognostic biomarker for lung cancer.
abstract: OBJECTIVE
  It has been reported that the type I interferon receptor subunit, interferon (alpha, beta and omega) receptor 2 (IFNAR2), is overexpressed in several malignancies, primarily adenocarcinomas (ADCs); however, the biological significance of IFNAR2 in human lung cancer has not yet been studied.
  
  
  METHODS
  Immunohistochemical analysis of 113 surgically resected lung specimens was performed, and the results were evaluated in association with clinical variables, including survival. Serum concentrations of IFNAR2 were also determined by an enzyme-linked immunosorbent assay in 157 lung cancer patients and 164 healthy volunteers.
  
  
  RESULTS
  IFNAR2 overexpression was observed in all histological types of lung cancer examined. Furthermore, strong IFNAR2 expression was associated with shorter progression-free survival (PFS) and overall survival (OS) (p < 0.0001 and p = 0.0110, respectively) in non-small cell lung cancer patients. Multivariate analyses confirmed its independent prognostic value for PFS and OS (p < 0.0001 and p = 0.0222, respectively). IFNAR2 serum levels were also significantly higher in lung cancer patients than in healthy volunteers (p < 0.0001).
  
  
  CONCLUSIONS
  IFNAR2 overexpression was observed in various histological types of lung cancer, and appears to be associated with lung cancers that behave aggressively. The results of this study strongly support the potential of IFNAR2 to be a prognostic biomarker for lung cancer.
authors.affiliation: Department of Molecular and Internal Medicine, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan.
authors.forename: Sonosuke
authors.initials: S
authors.lastname: Tanaka
authors.forename: Noboru
authors.initials: N
authors.lastname: Hattori
authors.forename: Nobuhisa
authors.initials: N
authors.lastname: Ishikawa
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Horimasu
authors.forename: Naoko
authors.initials: N
authors.lastname: Deguchi
authors.forename: Atsushi
authors.initials: A
authors.lastname: Takano
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Tomoda
authors.forename: Koji
authors.initials: K
authors.lastname: Yoshioka
authors.forename: Kazunori
authors.initials: K
authors.lastname: Fujitaka
authors.forename: Koji
authors.initials: K
authors.lastname: Arihiro
authors.forename: Morihito
authors.initials: M
authors.lastname: Okada
authors.forename: Akihito
authors.initials: A
authors.lastname: Yokoyama
authors.forename: Nobuoki
authors.initials: N
authors.lastname: Kohno
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood / Q000378:metabolism*; D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D053633:Receptor, Interferon alpha-beta / Q000097:blood / Q000378:metabolism*
chemical_list: D014408:Biomarkers, Tumor; C508033:IFNAR2 protein, human; D053633:Receptor, Interferon alpha-beta